Compare Novavax Inc (NVAX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Recursion Pharmaceuticals Inc — how do they compare? Novavax Inc trades at $8.06 (market cap $1.30B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | RXRX | |
|---|---|---|
Market Cap | $1.30B | $1.53B |
Sector | Health | Health |
52-Week High | $11.19 | $6.79 |
52-Week Low | $6.22 | $2.84 |
Enterprise Value | $800.50M | $946.50M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
